| Safety and efficacy of bivalirudin in acute coronary syndromes. | |
| | |
MedLine Citation:
|
PMID: 18473866 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Antithrombotic and powerful antiplatelet therapies, in addition to early percutaneous coronary intervention (PCI) are considered the treatment of choice for moderate- to high-risk patients with acute coronary syndromes (ACS; unstable angina and non-ST-segment elevation myocardial infarction). However, despite the integration of newer therapies including stents, glycoprotein IIb/IIIa inhibitors (GPI), and thienopyridines, the rate of adverse ischemic events still remains unacceptably high. Intensive pharmacologic regimens used to stabilize the disrupted atherosclerotic plaque and support angioplasty as well as surgical revascularization procedures, elicit a high rate of bleeding complications. Recent trials (ACUITY and HORIZONS studies) added evidence regarding safety and efficacy of bivalirudin use in acute coronary syndromes. In summary, is has been shown that bivalirudin alone is safe and effective in the vast majority of patients suffering from acute coronary syndromes and being treated invasively. The cost-effectiveness of such an approach will have to be determined. It remains to be a matter of discussion whether there are still patient subgroups being in need of more aggressive treatment strategies including GPI. In practice, it might be reasonable to perform a baseline assessment of hemorrhagic risk facilitating the choice of an antithrombotic regimen with a favourable safety and efficacy profile. With this tailored therapy it might be possible to further improve outcomes for individual patients with ACS. |
| | |
Authors:
|
F Hartmann |
Related Documents
:
|
19804096 - Clopidogrel: cardiologists' panacea or neurologists' headache? 11025346 - Update on the management of acute coronary syndromes. 15199446 - Low-molecular-weight heparins for the treatment of acute coronary syndromes. 11316916 - Benefit of adp receptor antagonists in atherothrombotic patients: new evidence. 15020586 - Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potentia... 2485026 - Functional significance of contractile proteins in cardiac hypertrophy and failure. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current pharmaceutical design Volume: 14 ISSN: 1873-4286 ISO Abbreviation: Curr. Pharm. Des. Publication Date: 2008 |
Date Detail:
|
Created Date: 2008-05-13 Completed Date: 2008-07-16 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9602487 Medline TA: Curr Pharm Des Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 1191-6 Citation Subset: IM |
Affiliation:
|
University Hospital Lübeck, Medical Clinic 2, Ratzeburger Allee 160, 23538 Lübeck, Germany. Franz.Hartmann@uk-sh.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acute Coronary Syndrome
/
drug therapy* Angina, Unstable / drug therapy Angioplasty, Transluminal, Percutaneous Coronary Anticoagulants* / adverse effects, therapeutic use Fibrinolytic Agents / therapeutic use Hemorrhage / chemically induced Heparin / adverse effects, therapeutic use Hirudin Therapy Hirudins* / adverse effects Humans Myocardial Infarction / drug therapy Peptide Fragments* / adverse effects, therapeutic use Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors Recombinant Proteins / adverse effects, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Anticoagulants; 0/Fibrinolytic Agents; 0/Hirudins; 0/Peptide Fragments; 0/Platelet Glycoprotein GPIIb-IIIa Complex; 0/Recombinant Proteins; 128270-60-0/bivalirudin; 9005-49-6/Heparin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Factor Xa inactivation in acute coronary syndrome.
Next Document: Pharmacoeconomics of anticoagulants in acute coronary syndrome and percutaneous coronary interventio...